In this second part of his interview with Managed Healthcare Executive, John B. Buse, M.D., Ph.D., a professor at the University of North Carolina (UNC) School of Medicine and director of the UNC's Diabetes Care Center, discusses lifestyle management and GLP-1s.
In this second part of his interview with Managed Healthcare Executive, John B. Buse, M.D., Ph.D., a professor at the University of North Carolina (UNC) School of Medicine and director of the UNC's Diabetes Care Center, discusses lifestyle management and GLP-1s.
He noted that the GLP-1 trials included lifestyle management: "It is not instead of lifestyle management," he said, referring to taking GLP-1s. "It is really an adjunct to lifestyle management."
He quickly added that for some people it is an absolutely essential adjunct. Buse said that in the United States, with people being busy and sometimes holding two jobs, eating a healthy diet consistently and getting physical activity regularly is "very, very hard to do."
Women with Pulmonary Arterial Hypertension Face Significant Disease Burden | ACC 2025
April 1st 2025A small, multi-country analysis of women of child-rearing age has found that these patients experience limits on activities of daily living, challenges with the healthcare system and a high overall financial burden.
Read More
Monoclonal Antibody Bentracimab Shown to Reverse Antiplatelet Effect of Brilinta | ACC 2025
April 1st 2025A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of Brilinta for patients who have bleeding events or who need urgent surgery.
Read More
Unrealistic Portrayals of Cardiac Arrest in Contemporary Film | ACC 2025
March 31st 2025Cardiac arrests in contemporary film are largely inaccurate when it comes to survival rate and etiology, according to a poster presented today at the American College of Cardiology conference held March 29 to 31 in Chicago.
Read More
Positive Results for Tirzepatide in Those With the Cardiovascular-Kidney-Metabolic Triad | ACC 2025
March 31st 2025Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with chronic kidney disease as those without it, and there are signals that it has benefits for renal function.
Read More